H19-Dependent Transcriptional Regulation of β3 and β4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer

Lorenza Bacci, Aurora Aiello, Cristian Ripoli, Rossella Loria, Dario Pugliese, Francesco Pierconti, Dante Rotili, Lidia Strigari, Francesco Pinto, Pier Francesco Bassi, Antonello Mai, Claudio Grassi, Alfredo Pontecorvi, Rita Falcioni, Antonella Farsetti, Simona NanniInternational Journal of Molecular Sciences 2019 · DOI

TL;DR

This study reveals how estrogen and hypoxia, common in the prostate cancer microenvironment, synergistically downregulate the long non-coding RNA H19. This H19 reduction, in turn, promotes the expression of specific integrins (β3 and β4), shifting prostate cancer cells towards a more aggressive, β-integrin-mediated metastatic pathway. This discovery offers potential new therapeutic targets for advanced prostate cancer.

What Problem Does This Paper Address?

Prostate cancer (PCa) is a significant health concern, and while localized disease is often treatable, recurrence and metastasis pose a major challenge. The tumor microenvironment, characterized by factors like estrogen and hypoxia, is known to drive aggressive phenotypes. However, the precise molecular mechanisms by which these factors interact to promote metastasis, particularly the role of long non-coding RNAs (lncRNAs) like H19, remain largely unexplored. This paper aims to dissect the contribution of H19 to PCa metastatic potential under the combined influence of estrogen and hypoxia, a critical but understudied aspect of PCa progression.

Methods

The researchers employed a multi-pronged approach:

  • Molecular Analysis: Quantitative PCR (qPCR) and Western blotting were used to measure the expression levels of H19, cell adhesion molecules (like E-cadherin, β3 and β4 integrins), and EMT-related genes.
  • Mechanistic Investigations: Chromatin immunoprecipitation (ChIP) assays were used to study the binding of key proteins (ERβ, HIF-2α, eNOS, EZH2) to the H19 promoter and target gene promoters. Overexpression and silencing (siRNA) experiments were conducted to manipulate H19 and HIF-2α levels.
  • Functional Assays: In vitro assays were used to assess PCa cells' metastatic potential, including cell-cell adhesion, motility (scratch test, laminin 5 motility test), and invasion (trans-well invasion assay).
  • Ex Vivo Validation: Organotypic slice cultures (OSCs) derived from human prostate tumors were used to validate findings in a more complex, tissue-like environment.
  • Epigenetic Modulation: The effects of epigenetic drugs targeting EZH2 and JMJD3 were investigated to understand their impact on the H19/integrin pathway and invasion.

Datasets

Not discussed in the paper. The study primarily utilizes established human prostate cancer cell lines (C27IM, C38IM, PC3), normal human umbilical vein endothelial cells (HUVECs), renal carcinoma cells (786-O), and ex vivo organotypic slice cultures from prostate cancer patients.

Key Insights and Ideas

  • Synergistic Repression of H19: The most striking finding is that while estrogen and hypoxia individually can induce H19 expression, their combined presence leads to a significant downregulation of H19. This is counterintuitive and suggests a complex interplay.
  • H19 as a Repressor of Cell Adhesion Molecules: The study establishes H19 as a transcriptional repressor of key cell adhesion molecules, specifically E-cadherin, β3 integrin, and β4 integrin. When H19 is silenced, these molecules are upregulated.
  • Shift in Metastatic Mechanism: The combined treatment, by downregulating H19 and upregulating β3/β4 integrins, appears to shift the metastatic strategy from an epithelial-to-mesenchymal transition (EMT)-driven process to a β-integrin-mediated invasion. This suggests a more cohesive, potentially more aggressive form of metastasis.
  • HIF-2α's Role in H19 Regulation: Mechanistically, the downregulation of H19 under combined stimuli appears to be mediated by HIF-2α, not HIF-1α, highlighting isoform-specific roles of hypoxia-inducible factors.
  • Epigenetic Control: The study implicates the EZH2/H3K27me3 epigenetic machinery in H19's repressive function, with H19 interacting with EZH2 to modulate histone methylation on target gene promoters.
  • Ex Vivo Relevance: The findings were corroborated in organotypic slice cultures from human prostate tumors, suggesting their relevance in a clinical context.

Key Results

  • Combined estrogen and hypoxia treatment significantly downregulated H19 expression in aggressive PCa cells and OSCs.
  • H19 silencing led to the upregulation of E-cadherin, β3 integrin, and β4 integrin mRNA and protein levels.
  • Combined treatment increased cell motility and invasion of PCa cells.
  • The study demonstrated that H19, in complex with EZH2, represses the transcription of CDH1, ITGB3, and ITGB4 by increasing H3K27me3 levels on their promoters.
  • Inhibition of JMJD3 (a histone demethylase) with GSK-J4 restored basal levels of H3K27me3 and significantly reduced invasion in combined treatment conditions.

Limitations and Future Work

  • Limited Sample Size for OSCs: While promising, the ex vivo studies used a small number of samples (n=5 for H19, n=3 for integrins), necessitating further validation in larger cohorts.
  • In Vitro vs. In Vivo: The study relies heavily on in vitro cell culture models and ex vivo explants. Future work should focus on in vivo animal models to fully elucidate the complex interplay of these factors in a living organism.
  • Therapeutic Translation: While the study identifies a potential therapeutic target (H19/integrin pathway) and shows promise with epigenetic drugs like GSK-J4, further pre-clinical and clinical studies are required to evaluate their efficacy and safety as anti-tumor agents.
  • Broader Role of H19: The study focuses on β3 and β4 integrins. Further investigation into H19's regulation of other cell adhesion molecules and its broader impact on PCa metastasis is warranted.

Summary updated

Abstract

Estrogen and hypoxia promote an aggressive phenotype in prostate cancer (PCa), driving transcription of progression-associated genes. Here, we molecularly dissect the contribution of long non-coding RNA H19 to PCa metastatic potential under combined stimuli, a topic largely uncovered. The effects of estrogen and hypoxia on H19 and cell adhesion molecules' expression were investigated in PCa cells and PCa-derived organotypic slice cultures (OSCs) by qPCR and Western blot. The molecular mechanism was addressed by chromatin immunoprecipitations, overexpression, and silencing assays. PCa cells' metastatic potential was analyzed by in vitro cell-cell adhesion, motility test, and trans-well invasion assay. We found that combined treatment caused a significant H19 down-regulation as compared with hypoxia. In turn, H19 acts as a transcriptional repressor of cell adhesion molecules, as revealed by up-regulation of both β3 and β4 integrins and E-cadherin upon H19 silencing or combined treatment. Importantly, H19 down-regulation and β integrins induction were also observed in treated OSCs. Combined treatment increased both cell motility and invasion of PCa cells. Lastly, reduction of β integrins and invasion was achieved through epigenetic modulation of H19-dependent transcription. Our study revealed that estrogen and hypoxia transcriptionally regulate, via H19, cell adhesion molecules redirecting metastatic dissemination from EMT to a β integrin-mediated invasion.
BibTeX
@article{bacci2019h,
  author = {Lorenza Bacci and Aurora Aiello and Cristian Ripoli and Rossella Loria and Dario Pugliese and Francesco Pierconti and Dante Rotili and Lidia Strigari and Francesco Pinto and Pier Francesco Bassi and Antonello Mai and Claudio Grassi and Alfredo Pontecorvi and Rita Falcioni and Antonella Farsetti and Simona Nanni},
  title = {{H19-Dependent Transcriptional Regulation of β3 and β4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer}},
  journal = {International Journal of Molecular Sciences},
  year = {2019},
  doi = {10.3390/ijms20164012},
}
Figure